Skip to main content
Top
Published in: European Journal of Epidemiology 11/2019

Open Access 01-11-2019 | Infertility | CANCER

Assisted reproductive technology and risk of ovarian cancer and borderline tumors in parous women: a population-based cohort study

Authors: Frida E. Lundberg, Anna L. V. Johansson, Kenny Rodriguez-Wallberg, Kristina Gemzell-Danielsson, Anastasia N. Iliadou

Published in: European Journal of Epidemiology | Issue 11/2019

Login to get access

Abstract

The study aimed to investigate if assisted reproductive technology (ART) treatment or a diagnosis of infertility were associated with the risk of ovarian cancer or borderline ovarian tumors (BOT) in parous women. In a population-based register study of 1,340,097 women with a first live birth in Sweden 1982–2012, the relationship between ART treatments, infertility and incidence of ovarian cancer or BOT were investigated using Cox regression analysis. In the cohort, 38,025 women gave birth following ART, 49,208 following an infertility diagnosis but no ART and 1,252,864 without infertility diagnosis or ART. During follow-up, 991 women were diagnosed with ovarian cancer and 747 with BOT. Women who gave birth following ART had higher incidence of both ovarian cancer (adjusted hazard ratio [aHR] 2.43, 95% confidence interval [CI] 1.73–3.42) and BOT (aHR 1.91, 95% CI 1.27–2.86), compared to women without infertility. Compared to women with infertility diagnoses and non-ART births, women with ART births also had a higher incidence of ovarian cancer (aHR 1.79, 95% CI 1.18–2.71) and BOT (aHR 1.48, 95% CI 0.90–2.44). Our results suggest that women who have gone through ART have a higher risk of ovarian cancer and BOT. At least part of that risk seems to be due to the underlying infertility and not the treatment per se, since the increased risk was smaller when comparing to other infertile women. As ART treatments are becoming more common and ovarian cancer usually occur in women of advanced age, larger studies with longer follow-up are needed in order to confirm or refute our findings.
Appendix
Available only for authorised users
Literature
1.
go back to reference Practice Committee of the American Society for Reproductive Medicine. Fertility drugs and cancer: a guideline. Fertil Steril. 2016;106:1617–26.CrossRef Practice Committee of the American Society for Reproductive Medicine. Fertility drugs and cancer: a guideline. Fertil Steril. 2016;106:1617–26.CrossRef
2.
go back to reference Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.CrossRef Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.CrossRef
3.
go back to reference Davidson B, Tropé CG. Ovarian cancer: diagnostic, biological and prognostic aspects. Womens Health (Lond). 2014;10(5):519–33.CrossRef Davidson B, Tropé CG. Ovarian cancer: diagnostic, biological and prognostic aspects. Womens Health (Lond). 2014;10(5):519–33.CrossRef
4.
go back to reference Whiteman DC, Siskind V, Purdie DM, Green AC. Timing of pregnancy and the risk of epithelial ovarian cancer. Cancer Epidemiol Biomark Prev. 2003;12:42–6. Whiteman DC, Siskind V, Purdie DM, Green AC. Timing of pregnancy and the risk of epithelial ovarian cancer. Cancer Epidemiol Biomark Prev. 2003;12:42–6.
5.
go back to reference Wu AH, Pearce CL, Lee AW, Tseng C, Jotwani A, Patel P, et al. Timing of births and oral contraceptive use influences ovarian cancer risk. Int J Cancer. 2017;141:2392–9.CrossRef Wu AH, Pearce CL, Lee AW, Tseng C, Jotwani A, Patel P, et al. Timing of births and oral contraceptive use influences ovarian cancer risk. Int J Cancer. 2017;141:2392–9.CrossRef
6.
go back to reference Lundberg FE, Iliadou AN, Rodriguez-Wallberg K, Gemzell-Danielsson K, Johansson ALV. The risk of breast and gynecological cancer in women with a diagnosis of infertility: a nationwide population-based study. Eur J Epidemiol. 2019;34(5):499–507.CrossRef Lundberg FE, Iliadou AN, Rodriguez-Wallberg K, Gemzell-Danielsson K, Johansson ALV. The risk of breast and gynecological cancer in women with a diagnosis of infertility: a nationwide population-based study. Eur J Epidemiol. 2019;34(5):499–507.CrossRef
7.
go back to reference Stewart LM, Holman CD, Aboagye-Sarfo P, Finn JC, Preen DB, Hart R. In vitro fertilization, endometriosis, nulliparity and ovarian cancer risk. Gynecol Oncol. 2013;128:260–4.CrossRef Stewart LM, Holman CD, Aboagye-Sarfo P, Finn JC, Preen DB, Hart R. In vitro fertilization, endometriosis, nulliparity and ovarian cancer risk. Gynecol Oncol. 2013;128:260–4.CrossRef
8.
go back to reference Buis CC, van Leeuwen FE, Mooij TM, Burger CW, OMEGA Project Group. Increased risk for ovarian cancer and borderline ovarian tumours in subfertile women with endometriosis. Hum Reprod. 2013;28:3358–69.CrossRef Buis CC, van Leeuwen FE, Mooij TM, Burger CW, OMEGA Project Group. Increased risk for ovarian cancer and borderline ovarian tumours in subfertile women with endometriosis. Hum Reprod. 2013;28:3358–69.CrossRef
9.
go back to reference Cirillo PM, Wang ET, Cedars MI, Chen L, Cohn BA. Irregular menses predicts ovarian cancer: prospective evidence from the Child Health and Development Studies. Int J Cancer. 2016;139:1009–17.CrossRef Cirillo PM, Wang ET, Cedars MI, Chen L, Cohn BA. Irregular menses predicts ovarian cancer: prospective evidence from the Child Health and Development Studies. Int J Cancer. 2016;139:1009–17.CrossRef
10.
go back to reference Cetin I, Cozzi V, Antonazzo P. Infertility as a cancer risk factor: a review. Placenta. 2008;29(Suppl B):169–77.CrossRef Cetin I, Cozzi V, Antonazzo P. Infertility as a cancer risk factor: a review. Placenta. 2008;29(Suppl B):169–77.CrossRef
11.
go back to reference Jensen A, Sharif H, Olsen JH, Kjaer SK. Risk of breast cancer and gynecologic cancers in a large population of nearly 50,000 infertile Danish women. Am J Epidemiol. 2008;168:49–57.CrossRef Jensen A, Sharif H, Olsen JH, Kjaer SK. Risk of breast cancer and gynecologic cancers in a large population of nearly 50,000 infertile Danish women. Am J Epidemiol. 2008;168:49–57.CrossRef
12.
go back to reference Reigstad MM, Storeng R, Myklebust TÅ, Oldereid NB, Omland AK, Robsahm TE, et al. Cancer risk in women treated with fertility drugs according to parity status: a registry-based cohort study. Cancer Epidemiol Biomark Prev. 2017;26:953–62.CrossRef Reigstad MM, Storeng R, Myklebust TÅ, Oldereid NB, Omland AK, Robsahm TE, et al. Cancer risk in women treated with fertility drugs according to parity status: a registry-based cohort study. Cancer Epidemiol Biomark Prev. 2017;26:953–62.CrossRef
13.
go back to reference Kessous R, Davidson E, Meirovitz M, Sergienko R, Sheiner E. The risk of female malignancies after fertility treatments: a cohort study with 25-year follow-up. J Cancer Res Clin Oncol. 2016;142:287–93.CrossRef Kessous R, Davidson E, Meirovitz M, Sergienko R, Sheiner E. The risk of female malignancies after fertility treatments: a cohort study with 25-year follow-up. J Cancer Res Clin Oncol. 2016;142:287–93.CrossRef
14.
go back to reference Reigstad MM, Larsen IK, Myklebust TA, Robsahm TE, Oldereid NB, Omland AK, et al. Cancer risk among parous women following assisted reproductive technology. Hum Reprod. 2015;30:1952–63.CrossRef Reigstad MM, Larsen IK, Myklebust TA, Robsahm TE, Oldereid NB, Omland AK, et al. Cancer risk among parous women following assisted reproductive technology. Hum Reprod. 2015;30:1952–63.CrossRef
15.
go back to reference Yli-Kuha AN, Gissler M, Klemetti R, Luoto R, Hemminki E. Cancer morbidity in a cohort of 9175 Finnish women treated for infertility. Hum Reprod. 2012;27:1149–55.CrossRef Yli-Kuha AN, Gissler M, Klemetti R, Luoto R, Hemminki E. Cancer morbidity in a cohort of 9175 Finnish women treated for infertility. Hum Reprod. 2012;27:1149–55.CrossRef
16.
go back to reference Källén B, Finnström O, Lindam A, Nilsson E, Nygren KG, Olausson PO. Malignancies among women who gave birth after in vitro fertilization. Hum Reprod. 2011;26:253–8.CrossRef Källén B, Finnström O, Lindam A, Nilsson E, Nygren KG, Olausson PO. Malignancies among women who gave birth after in vitro fertilization. Hum Reprod. 2011;26:253–8.CrossRef
17.
go back to reference Luke B, Brown MB, Spector LG, Missmer SA, Leach RE, Williams M, et al. Cancer in women after assisted reproductive technology. Fertil Steril. 2015;104:1218–26.CrossRef Luke B, Brown MB, Spector LG, Missmer SA, Leach RE, Williams M, et al. Cancer in women after assisted reproductive technology. Fertil Steril. 2015;104:1218–26.CrossRef
18.
go back to reference Williams CL, Jones ME, Swerdlow AJ, Botting BJ, Davies MC, Jacobs I, et al. Risks of ovarian, breast, and corpus uteri cancer in women treated with assisted reproductive technology in Great Britain, 1991–2010: data linkage study including 2.2 million person years of observation. BMJ. 2018;362:2644.CrossRef Williams CL, Jones ME, Swerdlow AJ, Botting BJ, Davies MC, Jacobs I, et al. Risks of ovarian, breast, and corpus uteri cancer in women treated with assisted reproductive technology in Great Britain, 1991–2010: data linkage study including 2.2 million person years of observation. BMJ. 2018;362:2644.CrossRef
19.
go back to reference Brinton LA, Trabert B, Shalev V, Lunenfeld E, Sella T, Chodick G. In vitro fertilization and risk of breast and gynecologic cancers: a retrospective cohort study within the Israeli Maccabi Healthcare Services. Fertil Steril. 2013;99:1189–96.CrossRef Brinton LA, Trabert B, Shalev V, Lunenfeld E, Sella T, Chodick G. In vitro fertilization and risk of breast and gynecologic cancers: a retrospective cohort study within the Israeli Maccabi Healthcare Services. Fertil Steril. 2013;99:1189–96.CrossRef
20.
go back to reference van Leeuwen FE, Klip H, Mooij TM, van de Swaluw AM, Lambalk CB, Kortman M, et al. Risk of borderline and invasive ovarian tumours after ovarian stimulation for in vitro fertilization in a large Dutch cohort. Hum Reprod. 2011;26:3456–65.CrossRef van Leeuwen FE, Klip H, Mooij TM, van de Swaluw AM, Lambalk CB, Kortman M, et al. Risk of borderline and invasive ovarian tumours after ovarian stimulation for in vitro fertilization in a large Dutch cohort. Hum Reprod. 2011;26:3456–65.CrossRef
21.
go back to reference Stewart LM, Holman CD, Finn JC, Preen DB, Hart R. In vitro fertilization is associated with an increased risk of borderline ovarian tumours. Gynecol Oncol. 2013;129:372–6.CrossRef Stewart LM, Holman CD, Finn JC, Preen DB, Hart R. In vitro fertilization is associated with an increased risk of borderline ovarian tumours. Gynecol Oncol. 2013;129:372–6.CrossRef
22.
go back to reference Skírnisdóttir I, Garmo H, Wilander E, Holmberg L. Borderline ovarian tumors in Sweden 1960–2005: trends in incidence and age at diagnosis compared to ovarian cancer. Int J Cancer. 2008;123:1897–901.CrossRef Skírnisdóttir I, Garmo H, Wilander E, Holmberg L. Borderline ovarian tumors in Sweden 1960–2005: trends in incidence and age at diagnosis compared to ovarian cancer. Int J Cancer. 2008;123:1897–901.CrossRef
23.
go back to reference SCB, Background Facts, Population and Welfare Statistics 2013:1. Multi-generation register 2012. A description of contents and quality. Statistics Sweden; 2013. SCB, Background Facts, Population and Welfare Statistics 2013:1. Multi-generation register 2012. A description of contents and quality. Statistics Sweden; 2013.
24.
go back to reference Socialstyrelsen. Kvalitet och innehåll i patientregistret. Utskrivningar från slutenvården 1964–2007 och besök i specialiserad öppenvård (exklusive primärvårdsbesök) 1997–2007. The National Board of Health and Welfare; 2009. Socialstyrelsen. Kvalitet och innehåll i patientregistret. Utskrivningar från slutenvården 1964–2007 och besök i specialiserad öppenvård (exklusive primärvårdsbesök) 1997–2007. The National Board of Health and Welfare; 2009.
25.
go back to reference World Health Organization. Statistical code for human tumours, WHO/HS-/CANC, 24.1 and 24.2. Geneva; 1956. World Health Organization. Statistical code for human tumours, WHO/HS-/CANC, 24.1 and 24.2. Geneva; 1956.
26.
go back to reference Barlow L, Westergren K, Holmberg L, Talbäck M. The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol. 2009;48:27–33.CrossRef Barlow L, Westergren K, Holmberg L, Talbäck M. The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol. 2009;48:27–33.CrossRef
27.
go back to reference Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23 257 women with ovarian cancer and 87 303 controls. Lancet. 2008;371:303–14.CrossRef Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23 257 women with ovarian cancer and 87 303 controls. Lancet. 2008;371:303–14.CrossRef
28.
go back to reference Official Statistics of Sweden Statistics—Health and Medical Care. Cancer Incidence in Sweden 2011. National Board of Health and Welfare; 2012. Official Statistics of Sweden Statistics—Health and Medical Care. Cancer Incidence in Sweden 2011. National Board of Health and Welfare; 2012.
Metadata
Title
Assisted reproductive technology and risk of ovarian cancer and borderline tumors in parous women: a population-based cohort study
Authors
Frida E. Lundberg
Anna L. V. Johansson
Kenny Rodriguez-Wallberg
Kristina Gemzell-Danielsson
Anastasia N. Iliadou
Publication date
01-11-2019
Publisher
Springer Netherlands
Published in
European Journal of Epidemiology / Issue 11/2019
Print ISSN: 0393-2990
Electronic ISSN: 1573-7284
DOI
https://doi.org/10.1007/s10654-019-00540-3

Other articles of this Issue 11/2019

European Journal of Epidemiology 11/2019 Go to the issue